Stop Sitting on Our RAASes: Get Moving with the Most Effective Care for Our Patients.
作者信息
Lafayette Richard A
机构信息
Stanford University Medical Center, Stanford, California.
出版信息
J Am Soc Nephrol. 2024 Nov 1;35(11):1610-1612. doi: 10.1681/ASN.0000000000000473. Epub 2024 Aug 5.
Abstract
摘要
相似文献
1
Stop Sitting on Our RAASes: Get Moving with the Most Effective Care for Our Patients.别再对我们的肾素-血管紧张素-醛固酮系统（RAAS）坐视不管：采取行动，为我们的患者提供最有效的治疗。
J Am Soc Nephrol. 2024 Nov 1;35(11):1610-1612. doi: 10.1681/ASN.0000000000000473. Epub 2024 Aug 5.
2
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.评估胰高血糖素样肽-1受体激动剂（GLP-1 RAs）减肥效果的网状Meta分析的数量、质量及结果：一项范围综述
Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.
3
Antidepressants for pain management in adults with chronic pain: a network meta-analysis.抗抑郁药治疗成人慢性疼痛的疼痛管理：一项网络荟萃分析。
Health Technol Assess. 2024 Oct;28(62):1-155. doi: 10.3310/MKRT2948.
4
Effectiveness and cost-effectiveness of computer and other electronic aids for smoking cessation: a systematic review and network meta-analysis.计算机和其他电子戒烟辅助手段的有效性和成本效益：系统评价和网络荟萃分析。
Health Technol Assess. 2012;16(38):1-205, iii-v. doi: 10.3310/hta16380.
5
Positioning for lumbar puncture in newborn infants.新生儿腰椎穿刺的定位。
Cochrane Database Syst Rev. 2023 Dec 14;12(12):CD015592. doi: 10.1002/14651858.CD015592.pub3.
6
Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism.对有静脉血栓栓塞风险的住院患者实施血栓预防的干预措施。
Cochrane Database Syst Rev. 2018 Apr 24;4(4):CD008201. doi: 10.1002/14651858.CD008201.pub3.
7
Oral adsorbents for preventing or delaying the progression of chronic kidney disease.用于预防或延缓慢性肾脏病进展的口服吸附剂。
Cochrane Database Syst Rev. 2014 Oct 15;2014(10):CD007861. doi: 10.1002/14651858.CD007861.pub2.
8
Quality improvement strategies for diabetes care: Effects on outcomes for adults living with diabetes.糖尿病护理质量改进策略：对成年糖尿病患者结局的影响。
Cochrane Database Syst Rev. 2023 May 31;5(5):CD014513. doi: 10.1002/14651858.CD014513.
9
Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis.帕金森病患者的体育锻炼：系统评价与网状Meta分析
Cochrane Database Syst Rev. 2024 Apr 8;4(4):CD013856. doi: 10.1002/14651858.CD013856.pub3.
10
Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis.帕金森病患者的身体锻炼：系统评价和网络荟萃分析。
Cochrane Database Syst Rev. 2023 Jan 5;1(1):CD013856. doi: 10.1002/14651858.CD013856.pub2.
本文引用的文献
1
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.司美格鲁肽对 2 型糖尿病患者慢性肾脏病的影响。
N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24.
2
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.在 IgA 肾病患者中，sparsentan 对比厄贝沙坦的疗效和安全性（PROTECT）：一项随机、活性对照、3 期临床试验的 2 年结果。
Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3.
3
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.在原发性 IgA 肾病（NefIgArd）患者中，布地奈德靶向释放制剂的疗效和安全性：一项随机 3 期临床试验的 2 年结果。
Lancet. 2023 Sep 9;402(10405):859-870. doi: 10.1016/S0140-6736(23)01554-4. Epub 2023 Aug 14.
4
Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease.克服实施慢性肾脏病新指南导向治疗的障碍。
Nephrol Dial Transplant. 2023 Feb 28;38(3):532-541. doi: 10.1093/ndt/gfac283.
5
Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence.心力衰竭和慢性肾脏病患者中指南推荐的药物治疗的使用：从医生的处方到患者的配药、药物依从性和持久性。
Eur J Heart Fail. 2022 Nov;24(11):2185-2195. doi: 10.1002/ejhf.2620. Epub 2022 Aug 2.
6
Avacopan for the Treatment of ANCA-Associated Vasculitis.阿伐考潘治疗抗中性粒细胞胞浆抗体相关性血管炎。
N Engl J Med. 2021 Feb 18;384(7):599-609. doi: 10.1056/NEJMoa2023386.
7
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.非奈利酮对 2 型糖尿病患者慢性肾脏病结局的影响。
N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23.
8
Dapagliflozin in Patients with Chronic Kidney Disease.达格列净治疗慢性肾脏病患者。
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
9
Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus.成年人糖尿病与非糖尿病患者慢性肾脏病快速进展的现代比率和预测因素。
BMC Nephrol. 2018 Jun 22;19(1):146. doi: 10.1186/s12882-018-0942-1.
10
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.托伐普坦治疗晚期常染色体显性遗传性多囊肾病。
N Engl J Med. 2017 Nov 16;377(20):1930-1942. doi: 10.1056/NEJMoa1710030. Epub 2017 Nov 4.
Zotero 插件